Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-02-13
DOI
10.3389/fendo.2023.1125693
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases
- (2022) Jonatan Barrera-Chimal et al. Annual Review of Physiology
- The Role of Aldosterone in OSA and OSA-Related Hypertension
- (2022) Yi Wang et al. Frontiers in Endocrinology
- Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
- (2022) Jennifer B Green et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
- (2022) Bingzi Dong et al. Frontiers in Endocrinology
- Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
- (2022) Srikanth Palanisamy et al. Cardiology and Therapy
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials
- (2022) Wujisiguleng Bao et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats
- (2022) Ly Tu et al. HYPERTENSION
- Analysis from the FIDELITY study examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
- (2022) George L. Bakris et al. KIDNEY INTERNATIONAL
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
- (2022) Muthiah Vaduganathan et al. LANCET
- Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
- (2022) Gerasimos Filippatos et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Effect of finerenone on the occurrence of vision‐threatening complications in patients with non‐proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants ( ReFineDR / DeFineDR )
- (2022) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db/db Mice
- (2021) Daigoro Hirohama et al. HYPERTENSION
- Semiquantitative assessed proteinuria and risk of heart failure: Analysis of a nationwide epidemiological database
- (2021) Akira Fukui et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
- (2021) Johannes J. Kovarik et al. Diabetes Therapy
- Mineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights
- (2021) Johann Bauersachs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- (2021) Gerasimos Filippatos et al. CIRCULATION
- Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
- (2021) Sebastiaan Camiel Goulooze et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
- (2021) Jonatan Barrera-Chimal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
- (2021) Rajiv Agarwal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Diagnosis and treatment of primary aldosteronism
- (2021) Martin Reincke et al. Lancet Diabetes & Endocrinology
- Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
- (2020) Nobuyuki Enzan et al. ESC Heart Failure
- The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway
- (2020) Vincenzo Marzolla et al. FASEB JOURNAL
- Aldosterone, Inflammation, Immune System, and Hypertension
- (2020) Nathanne S Ferreira et al. AMERICAN JOURNAL OF HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial
- (2020) Hitoshi Minakuchi et al. Scientific Reports
- A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy
- (2020) Mostafa El Mokadem et al. CardioRenal Medicine
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Mineralocorticoid Antagonism and Diabetic Kidney Disease
- (2019) Yuliya Lytvyn et al. Current Diabetes Reports
- Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis
- (2019) Chao Zuo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data
- (2018) Stefan Pilz et al. HORMONE AND METABOLIC RESEARCH
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant HypertensionNovelty and Significance
- (2018) Eduardo M. Krieger et al. HYPERTENSION
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure
- (2018) Hui Pei et al. MEDICINE
- Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
- (2018) Chen-Ta Yang et al. Journal of Clinical Medicine
- Canrenone on cardiovascular mortality in congestive heart failure
- (2018) Giuseppe Derosa et al. PHARMACOLOGICAL RESEARCH
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study
- (2017) Wei-Cheng Tseng et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension
- (2017) Toshiki Sawai et al. Journal of Clinical Hypertension
- Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension
- (2017) Tatjana Kalizki et al. Journal of Clinical Hypertension
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension
- (2017) Andreas Schneider et al. JOURNAL OF HYPERTENSION
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
- (2017) Jochen Dutzmann et al. PLoS One
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
- (2016) Nisa M. Maruthur et al. ANNALS OF INTERNAL MEDICINE
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
- (2015) Licette CY Liu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism
- (2015) Shigehiro Karashima et al. HYPERTENSION RESEARCH
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- The cardioprotective effects of mineralocorticoid receptor antagonists
- (2013) T.N.A. van den Berg et al. PHARMACOLOGY & THERAPEUTICS
- Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF)
- (2011) Anita Deswal et al. JOURNAL OF CARDIAC FAILURE
- Aldosterone: effects on the kidney and cardiovascular system
- (2010) Marie Briet et al. Nature Reviews Nephrology
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
- (2009) Alessandro Boccanelli et al. EUROPEAN JOURNAL OF HEART FAILURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started